Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development: | ||||
| Stock-based compensation | 8,070 | 4,318 | 12,945 | 7,649 |
| Other research and development | 87,267 | 27,464 | 130,788 | 70,495 |
| Total research and development | 95,337 | 31,782 | 143,733 | 78,144 |
| Selling, general and administrative: | ||||
| Stock-based compensation | 19,805 | 12,044 | 34,880 | 23,684 |
| Other selling, general and administrative | 62,325 | 43,541 | 135,467 | 82,232 |
| Total selling, general and administrative | 82,130 | 55,585 | 170,347 | 105,916 |
Document
FAQ
- What is TG Therapeutics's R&D?
- TG Therapeutics (TGTX) reported R&D of $95.34M in Q2 2026.
- How has TG Therapeutics's R&D changed year-over-year?
- TG Therapeutics's R&D increased by 200.0% year-over-year, from $31.78M to $95.34M.
- What is the long-term trend for TG Therapeutics's R&D?
- Over 4 years (2021 to 2025), TG Therapeutics's R&D has grown at a -7.9% compound annual growth rate (CAGR), from $222.58M to $160.22M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about TG Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude